Cite

HARVARD Citation

    Paz‐Ares, L. et al. (2022). RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer. Cancer. 128 (9), pp. 1801-1811. [Online]. 
  
Back to record